Apellis Pharmaceuticals (NASDAQ:APLS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM.
Here’s what investors need to know about the announcement.
Earnings
Apellis Pharmaceuticals missed estimated earnings by 7.35%, reporting an EPS of $-1.46 versus an estimate of $-1.36.
Revenue was up $15.70 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.1 which was followed by a 3.03% drop in the share price the next day.
Here’s a look at Apellis Pharmaceuticals’s past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -1.32 | -1.54 | -1.75 | -1.70 |
| EPS Actual | -1.42 | -1.61 | -1.57 | -2.72 |
| Revenue Estimate | 12.57M | 8.78M | 7.22M | 810K |
| Revenue Actual | 14.38M | 60.29M | 5.65M | 623K |
To track all earnings releases for Apellis Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
